Neurorehabilitation News

The FDA has granted 510(k) clearance to a gene therapy-enabling company for a system that aims for greater accuracy in the placement and operation of instruments or devices in procedures for neurological conditions.

“Is it all worth it?” reads the title of the Reddit post from an international medical graduate community. I wake up to these posts ever so frequently; I think to myself and slide the notification away.

The FDA has granted rare pediatric disease designation to an alpha-kinase 1 inhibitor to treat patients with retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache, or ROSAH, syndrome.

A Boston-area biotech company has received $24 million in Series A funding to develop neurorestorative and remyelinating therapies for a broad range of neurological conditions.

In a cohort of adults with traumatic brain injury, level of impairment for those who exhibited cognitive impairment after 6 months was directly correlated to TBI severity, according to research from JAMA Network Open.

Vanqua Bio has announced its lead candidate for Parkinson’s disease, a small molecule allosteric activator of glucocerebrosidase, will enter clinical development in the first quarter of 2024.

A clinical-stage biopharma firm announced it has been granted a U.S. patent expanding coverage of a novel oral therapy to treat various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein.

The FDA has approved a battery-powered rechargeable deep brain stimulation system for patients with Parkinson’s disease and other disorders such as essential tremor, epilepsy and dystonia, according to the manufacturer.

According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in confronting Huntington’s disease is halting neurodegeneration prior to the onset of symptoms.

The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.